[
  {
    "ts": null,
    "headline": "Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?",
    "summary": "Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain. Click to read why VRTX is a Buy.",
    "url": "https://finnhub.io/api/news?id=6723b8b091a6b77518608ce5f37e5c1eb72d9fc217c1ae3d6a56933a9ad8073b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747993615,
      "headline": "Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?",
      "id": 134660926,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2174377045/image_2174377045.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain. Click to read why VRTX is a Buy.",
      "url": "https://finnhub.io/api/news?id=6723b8b091a6b77518608ce5f37e5c1eb72d9fc217c1ae3d6a56933a9ad8073b"
    }
  }
]